All In Biotech

Drug Trial Radar · NCT05531097

Ascending Single-Dose and Multiple-Dose Study to Evaluate HSK31679 in Healthy Subjects and Subjects With Elevated LDL-C

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses and Multiple Dose of HSK31679 in Healthy Volunteers and Subjects With Elevated LDL-C

Last checked: Nov 20, 2026Latest source record: Jan 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

96

Actual

Start

Feb 22, 2022

Primary completion

Sep 21, 2022

Study completion Dec 8, 2022

Sponsor

Sponsor type
Industry
First posted
Sep 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I, single-dose and multiple dose escalation clinical trial for HSK31679 conducted in chinese healthy volunteers and LDL-C elevated subjects. The safety, tolerability, food-impact,pharmacokinetics and pharmacodynamics of HSK31679 tablet in healthy volunteers and LDL-C elevated volunteers will be evaluated using a randomized, double-blind, placebo-controlled trial design

Conditions

  • Healthy
  • Elevated LDL-C

Interventions

  • HSK31679Drug

    Single or multiple oral doses of HSK31679

  • PlaceboDrug

    Matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number and severity of treatment emergent adverse events (TEAEs) .Time frame: 5 days after single dose and 18 days after the first dose of multiple doses
  2. Changes from baseline in clinical laboratory parameters(Blood routine, blood biochemistry, Urine routine, Coagulation function, thyroid function and antibodies).Time frame: 5 days after single dose and 18 days after the first dose of multiple doses
  3. Changes from baseline in physical examination results(General condition skin mucous membrane superficial lymph nodes head neck chest abdomen spine limbs and others).Time frame: 5 days after single dose and 18 days after the first dose of multiple doses
  4. Changes from baseline in vital signs(Systolic and diastolic blood pressure, pulse, respiratory rate, body temperature).Time frame: 5 days after single dose and 18 days after the first dose of multiple doses
  5. Changes from baseline in 12-ECG(QT interval, QTcF interval, PR interval, QRS interval and RR interval).Time frame: 5 days after single dose and 18 days after the first dose of multiple doses

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Xiangya Hospital of Central South University

    Changsha, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.